Efficacy and safety of modified Sini San for treating poststroke depression : A meta-analysis of randomized controlled trials
Copyright © 2020. Published by Elsevier Inc..
OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy and safety of modified Sini San (MSS) for poststroke depression (PSD).
METHODS: Randomized controlled trials of MSS for PSD were identified in the Web of science, PsycINFO, World Cat, CNKI, VIP, Wanfang, DuXiu, and Embase databases according to the inclusion and exclusion criteria.
RESULTS: In total, 7 trials with 548 patients were included in the review. The meta-analysis showed that MSS had superior effects to fluoxetine hydrochloride in terms of response rate in patients with PSD (relative risk (RR): 1.19, 95% confidence interval (CI) [1.10, 1.28], Z = 4.31, P < 0.0001). MSS may be more effective at reducing Hamilton depression rating scale (HAMD) scores and modified Edinburgh-Scandinavia stroke scale (SSS) scores than fluoxetine hydrochloride after 4 and 8 weeks of treatment.
CONCLUSIONS: Our meta-analysis demonstrated that MSS appears to have excellent therapeutic effects on PSD and no serious adverse effects. However, due to the small sample sizes and low quality of the literature, studies with higher methodological quality, larger sample sizes, and placebo controls are recommended in future research on MSS in patients with PSD to enhance the strength of the evidence. Therefore, clinicians should be cautious in using this evidence to make clinical decisions.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Explore (New York, N.Y.) - 17(2021), 2 vom: 15. März, Seite 162-169 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cai, Lun [VerfasserIn] |
---|
Links: |
---|
Themen: |
Drugs, Chinese Herbal |
---|
Anmerkungen: |
Date Completed 03.11.2021 Date Revised 03.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.explore.2020.05.008 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM31106910X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM31106910X | ||
003 | DE-627 | ||
005 | 20231225141448.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.explore.2020.05.008 |2 doi | |
028 | 5 | 2 | |a pubmed24n1036.xml |
035 | |a (DE-627)NLM31106910X | ||
035 | |a (NLM)32527684 | ||
035 | |a (PII)S1550-8307(20)30164-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cai, Lun |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy and safety of modified Sini San for treating poststroke depression |b A meta-analysis of randomized controlled trials |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.11.2021 | ||
500 | |a Date Revised 03.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020. Published by Elsevier Inc. | ||
520 | |a OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy and safety of modified Sini San (MSS) for poststroke depression (PSD) | ||
520 | |a METHODS: Randomized controlled trials of MSS for PSD were identified in the Web of science, PsycINFO, World Cat, CNKI, VIP, Wanfang, DuXiu, and Embase databases according to the inclusion and exclusion criteria | ||
520 | |a RESULTS: In total, 7 trials with 548 patients were included in the review. The meta-analysis showed that MSS had superior effects to fluoxetine hydrochloride in terms of response rate in patients with PSD (relative risk (RR): 1.19, 95% confidence interval (CI) [1.10, 1.28], Z = 4.31, P < 0.0001). MSS may be more effective at reducing Hamilton depression rating scale (HAMD) scores and modified Edinburgh-Scandinavia stroke scale (SSS) scores than fluoxetine hydrochloride after 4 and 8 weeks of treatment | ||
520 | |a CONCLUSIONS: Our meta-analysis demonstrated that MSS appears to have excellent therapeutic effects on PSD and no serious adverse effects. However, due to the small sample sizes and low quality of the literature, studies with higher methodological quality, larger sample sizes, and placebo controls are recommended in future research on MSS in patients with PSD to enhance the strength of the evidence. Therefore, clinicians should be cautious in using this evidence to make clinical decisions | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Meta-analysis | |
650 | 4 | |a Post-stroke depression | |
650 | 4 | |a Sini San | |
650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
650 | 7 | |a modified sini |2 NLM | |
700 | 1 | |a Jiejie, Lin |e verfasserin |4 aut | |
700 | 1 | |a Hu, Yuying |e verfasserin |4 aut | |
700 | 1 | |a Chen, Wei |e verfasserin |4 aut | |
700 | 1 | |a Wei, Liping |e verfasserin |4 aut | |
700 | 1 | |a He, Qianchao |e verfasserin |4 aut | |
700 | 1 | |a Hu, Yueqiang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Explore (New York, N.Y.) |d 2005 |g 17(2021), 2 vom: 15. März, Seite 162-169 |w (DE-627)NLM163575134 |x 1878-7541 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2021 |g number:2 |g day:15 |g month:03 |g pages:162-169 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.explore.2020.05.008 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2021 |e 2 |b 15 |c 03 |h 162-169 |